Merck (MRK) Restructuring Costs (2009 - 2026)

Merck has disclosed Restructuring Costs across 18 years of filings, most recently posting $195.0 million for Q1 2026.

• In Q1 2026, Restructuring Costs rose 182.61% year-over-year to $195.0 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 296.48% YoY), while the FY2025 annual figure was $889.0 million, up 187.7% from the prior year.
• Restructuring Costs declined to $195.0 million in Q1 2026, from $213.0 million in the prior quarter.
• Over the last five years, Restructuring Costs for MRK reached as high as $560.0 million in Q2 2025 and fell as low as $47.0 million in Q3 2025.
• The 5-year median for Restructuring Costs is $94.0 million (2022), against an average of $137.1 million.
• Annual changes were most pronounced in 2022 — Restructuring Costs plunged 82.15% — and 2025, when it jumped 600.0%.
• A 5-year view of Restructuring Costs shows it stood at $49.0 million in 2022, then surged by 420.41% to $255.0 million in 2023, then plunged by 80.0% to $51.0 million in 2024, then jumped by 317.65% to $213.0 million in 2025, then slipped by 8.45% to $195.0 million in 2026.
• According to Business Quant data, Restructuring Costs over the past three periods registered $195.0 million, $213.0 million, and $47.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.